Tichenor Ventures

OS Therapies is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for osteosarcoma and other solid tumors. Initially focused on addressing the unmet need for new therapies in cancers of the bone, particularly in children and young adults, the company has since expanded its pipeline to include other solid tumors with similar recurrence mechanisms.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for patients with cancer and other serious conditions. The company focuses on targeting HIF-2a, a transcription factor previously considered difficult to address with small molecules. Its lead drug candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma, and it is being evaluated in various settings, including in patients with von Hippel-Lindau disease-associated renal cell carcinoma and in combination with cabozantinib. Additionally, Peloton is advancing PT2567, another oral HIF-2a inhibitor in preclinical development for non-oncology indications such as pulmonary arterial hypertension. Founded in 2010 and previously known as Damascus Pharmaceutics, Peloton Therapeutics aims to leverage its scientific expertise and collaborations to become a leading biotech company in the region.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for patients with cancer and other serious conditions. The company focuses on targeting HIF-2a, a transcription factor previously considered difficult to address with small molecules. Its lead drug candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma, and it is being evaluated in various settings, including in patients with von Hippel-Lindau disease-associated renal cell carcinoma and in combination with cabozantinib. Additionally, Peloton is advancing PT2567, another oral HIF-2a inhibitor in preclinical development for non-oncology indications such as pulmonary arterial hypertension. Founded in 2010 and previously known as Damascus Pharmaceutics, Peloton Therapeutics aims to leverage its scientific expertise and collaborations to become a leading biotech company in the region.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Incorporated in 2007 and headquartered in South San Francisco, California, the company is engaged in creating novel treatments informed by key biological pathways. Its product candidates include Aldafermin, an engineered variant of the FGF19 hormone currently in Phase 2b clinical trials for non-alcoholic steatohepatitis (NASH), and NGM313, an agonistic antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates in development include NGM395 for metabolic syndrome, NGM120 to address cancer anorexia/cachexia syndrome, NGM217 aimed at improving insulin production in diabetes patients, and NGM621 to target a protein involved in age-related macular degeneration. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and development efforts in creating impactful medicines that enhance patient health.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Incorporated in 2007 and headquartered in South San Francisco, California, the company is engaged in creating novel treatments informed by key biological pathways. Its product candidates include Aldafermin, an engineered variant of the FGF19 hormone currently in Phase 2b clinical trials for non-alcoholic steatohepatitis (NASH), and NGM313, an agonistic antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates in development include NGM395 for metabolic syndrome, NGM120 to address cancer anorexia/cachexia syndrome, NGM217 aimed at improving insulin production in diabetes patients, and NGM621 to target a protein involved in age-related macular degeneration. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and development efforts in creating impactful medicines that enhance patient health.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Incorporated in 2007 and headquartered in South San Francisco, California, the company is engaged in creating novel treatments informed by key biological pathways. Its product candidates include Aldafermin, an engineered variant of the FGF19 hormone currently in Phase 2b clinical trials for non-alcoholic steatohepatitis (NASH), and NGM313, an agonistic antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates in development include NGM395 for metabolic syndrome, NGM120 to address cancer anorexia/cachexia syndrome, NGM217 aimed at improving insulin production in diabetes patients, and NGM621 to target a protein involved in age-related macular degeneration. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and development efforts in creating impactful medicines that enhance patient health.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.